Eli Lilly and Company (NYSE: LLY) announced results from the long-term extension (LTE) of the Phase 3 TRAILBLAZER-ALZ 2 study ...

Kisunla’s active substance is donanemab, a monoclonal antibody that targets and clears amyloid-beta plaques in the brain, a ...

Findings from the TRAILBLAZER-ALZ 2 long-term extension study highlight Kisunla (donanemab-azbt) continued to demonstrate ...

Subtyping is what made precision medicine in cancer a reality. And for successful drug discovery in all its stages, finding ...

Results from the long-term extension of the Phase III TRAILBLAZER-ALZ 2 trial (NCT04437511) showed sustained benefits with ...

Long-term extension data presented at the Alzheimer's Association International Conference showed amyloid plaque ...

Kisunla, a newly approved Alzheimer's drug in Taiwan, would not be covered by the National Health Insurance (NHI) system, ...

Findings from the TRAILBLAZER-ALZ 2 long-term extension study highlight Kisunla continued to demonstrate slowing of decline, with most participants having completed ...

Four months after giving Eli Lilly’s Alzheimer’s disease treatment a thumbs-down, Europe’s Committee for Medicinal Products ...

New findings presented at the 2025 Alzheimer’s Association International Conference (AAIC) in Toronto spotlighted the long-term potential of two FDA-approved Alzheimer’s treatments for people with ...

Eli Lilly (NYSE: LLY) has been a terrific investment in recent years. Thanks to significant clinical progress and outstanding ...

The U.S. Food and Drug Administration approved changing the prescribing information for Eli Lilly's Alzheimer's drug Kisunla to allow more gradual dosing to lower the risk of a potentially dangerous ...